Skip to main content
main-content

14-12-2020 | SABCS 2020 | Conference coverage | Video

Entinostat addition fails to improve aromatase inhibitor-resistant breast cancer outcomes

Roisin Connolly discusses the next steps following the negative results of the phase 3 ECOG-ACRIN E2112 trial of the HDAC inhibitor entinostat in combination with endocrine therapy in aromatase inhibitor-resistant patients with advanced breast cancer (2:43).

Read transcript

2021 ASCO Annual Meeting coverage

Access news and expert commentary from the 2021 ASCO Annual Meeting

Image Credits